Phytoconstituents of Withania somnifera unveiled Ashwagandhanolide as a potential drug targeting breast cancer: Investigations through computational, molecular docking and conceptual DFT studies.

Breast cancer is the second most common malignancy in females worldwide and poses a great challenge that necessitates the identification of novel therapeutic agents from several sources. This research aimed to study the molecular docking and molecular dynamics simulations of four proteins (such as PDB: 6CBZ, 1FDW, 5GWK and 2WTT) with the selected phytochemicals from Withania somnifera to identify the potential inhibitors for breast cancer. The molecular docking result showed that among 44 compounds, two of them, Ashwagandhanolide and Withanolide sulfoxide have the potential to inhibit estrogen receptor alpha (ERα), 17-beta-hydroxysteroid -dehydrogenase type 1 (17ß-HSD1), topoisomerase II alpha (TOP2A) and p73 tetramerization domain that are expressed during breast cancer. The molecular dynamics (MD) simulations results suggested that Ashwagandhanolide remained inside the binding cavity of four targeted proteins and contributed favorably towards forming a stable protein-ligand complex throughout the simulation. Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties confirmed that Ashwagandhanolide is hydrophobic and has moderate intestinal permeability, good intestinal absorption, and poor skin permeability. The compound has a relatively low VDss value (-1.652) and can be transported across ABC transporter and good central nervous system (CNS) permeability but did not easily cross the blood-brain barrier (BBB). This compound does not possess any mutagenicity, hepatotoxicity and skin sensitization. Based on the results obtained, the present study highlights the anticancer potential of Ashwagandhanolide, a compound from W. somnifera. Furthermore, in vitro and in vivo studies are necessary to perform before clinical trials to prove the potentiality of Ashwagandhanolide.

Evaluation of Bacillus cereus and Bacillus pumilus metabolites for anthelmintic activity.

OBJECTIVE: To assess the anthelmintic acivity of Bacillus cereus and Bacillus pumilus metabolites. MATERIALS AND METHODS: The successive solvent extractions with petroleum ether, ethyl acetate and methanol. The solvent extracts were tested for anthelmintic activity against Pheretima posthuma at 20 mg/ml concentration. The time of paralysis and time of death of the worms was determined for all the extracts. Albendazole was taken as a standard reference and sterile water as a control. RESULTS: All the sample extracts showed significant anthelmintic activity in paralyzing the worms comparable with that of the standard drug. The time of death exhibited by BP metabolites was close to the time exhibited by standard. CONCLUSION: The study indicates both bacteria Bacillus cereus and Bacillus pumilus have anthelmintic activity indicating potential metabolites in them.

Synthesis, characterization and antimicrobial studies of some new quinoline incorporated benzimidazole derivatives.

Two new series of quinoline incorporated benzimidazole derivatives (4a-i and 8a-f) were synthesized from substituted aniline and isatin through multi-step reaction. 6-substituted-4-carboxyquinolines (3a,b and 7) were synthesized by multi component one pot reactions (via Doebner reaction and Pfitzinger reaction respectively) and the targeted benzimidazole derivatives were obtained by the reaction of 6-substituted-4-carboxyquinolines (3a,b and 7) with substituted aromatic diamines in acidic media. All the newly synthesized compounds were characterized by IR, NMR mass spectral study and also by C, H, N analyses. The final compounds were screened for their in-vitro antibacterial and antifungal activity by well plate method (zone of inhibition). The results revealed that, compounds 4c, 4d, 8c and 8d showed significant antibacterial activity. The compound 8b was found to be potent antifungal agent. 4a, 8a and 8f showed moderate to good antimicrobial activity as compared to the standard drugs against all tested microbial strains.

Bioaccumulation potential of Aspergillus niger and Aspergillus flavus for removal of heavy metals from paper mill effluent.

In the present study Aspergillus niger and Aspergillus flavus isolated from paper mill effluent showed tolerance and accumulation of toxic metals Ni, Zn, Cd, Pb, Cr and Cu from synthetic medium and paper mill effluent. Physico-chemical and heavy metals characterization of industrially treated paper mill effluent showed insignificant reduction in BOD, hardness, TDS and heavy metals as compared to permissible limits of BIS and WHO. A. niger and A. flavus were treated with synthetic medium containing 100-1000 mg l(-1) of six heavy metals. A. niger was able to tolerate and grow in 1000 mg l(-1) Pb, 500 mg l(-1) Cu, 250 mg l(-1) Zn and 100 mg l(-1) Cr, Ni respectively. No growth of A. niger was observed in 100 mg l-(-1) of Cd. A. flavus was capable to tolerate and grow in 1000 mg l(-1) Pb, Zn and Ni, 100mg l(-1) Cu. A. flavus growth was completely inhibited in 100 mg l(-1) of Cd and Cr. The Cd, Zn, Cu and Pb reduction were found significant (p < 0.05) in the paper effluent inoculated with A. niger and A. flavus biomass compared to industrial treated effluent. A. niger and A. flavus accumulated maximum of Pb (75.82%) followed by Zn (49.40%) > Cu (45.34%) > Ni (25.20%), while only 41% Cr was accumulated by A. nigerfrom 100 mg l(-1) of Cr solution.

Etiology and epidemiological analysis of glaucoma-filtering bleb infections in a tertiary eye care hospital in South India.

PURPOSE: To evaluate the microbial etiology and associated risk factors among patients with blebitis following trabeculectomy. MATERIALS AND METHODS: A retrospective analysis of all culture-proven blebitis was performed in patients who underwent trabeculectomy between January 2004 and December 2008. A standardized form was filled out for each patient, documenting sociodemographic features and information pertaining to risk factors. Swabbing of the infected bleb surface was performed for all suspected cases and further subjected to microbiological analysis. RESULTS: A total of 23 patients with culture-proven blebitis were treated during the study period, with a mean age of 59.2 years (59.2 ± SD: 12.8; range, 30-81 years). Duration of onset was early (≤ 36 months) in six (26%) cases and late (> 36 months) in 17 (74%) cases with a range between 15 and 144 months (mean, 82.91 months; SD: 41.89). All 23 blebs were located superiorly and of which, 21 (91%) were microcystic avascular, 1 (4%) diffuse avascular, and 1 (4%) vascular flattened. The predominant risk factor identified was bleb leak (35%; 8 of 23) followed by thin bleb (22%; 5 of 23) and blepharitis (17%; 4 of 23). Bleb leaks (100%) were recorded only in patients with late onset (≥ 9 years) of infection (P< 0.001), while the incidence of ocular surface disease (100%) occurred early (≤ 3 years) (P< 0.001). Use of topical steroids was associated frequently with cases of thin blebs (80%; 4 of 5) (P< 0.001), while topical antibiotics showed bleb leaks (88%; 7 of 8) (P< 0.001). Coagulase-positive staphylococci were frequently recovered from blebitis with thin blebs (71%; 5 of 7) (P = 0.001), Coagulase-negative staphylococci (CoNS) with bleb leak (100%; 8 of 8) (P< 0.001), Corynebacterium with blepharitis (100%; 3 of 3) (P = 0.001), and Streptococci with releasable sutures (75%; 3 of 4) (P = 0.001). CONCLUSION: Bleb leak is the principal risk factor responsible for late-onset blebitis, while early-onset blebitis could be ascribed to ocular surface diseases. Streptococci were mainly responsible for early onset of infection, while the late onset was due to CoNS.

Etiology and antibacterial susceptibility pattern of community-acquired bacterial ocular infections in a tertiary eye care hospital in south India.

AIMS: To identify the etiology, incidence and prevalence of ocular bacterial infections, and to assess the in vitro susceptibility of these ocular bacterial isolates to commonly used antibiotics. MATERIALS AND METHODS: Retrospective analysis of consecutive samples submitted for microbiological evaluation from patients who were clinically diagnosed with ocular infections and were treated at a tertiary eye care referral center in South India between January 2002 and December 2007. RESULTS: A total of 4417 ocular samples was submitted for microbiological evaluation, of which 2599 (58.8%) had bacterial growth, 456 (10.3%) had fungal growth, 15 (0.34%) had acanthamoebic growth, 14 (0.32%) had mixed microbial growth and the remaining 1333 (30.2%) had negative growth. The rate of culture-positivity was found to be 88% (P < 0.001) in eyelids' infection, 70% in conjunctival, 69% in lacrimal apparatus, 67.4% in corneal, 51.6% in intraocular tissues, 42.9% in orbital and 39.2% in scleral infections. The most common bacterial species isolated were Staphylococcus aureus (26.69%) followed by Streptococcus pneumoniae (22.14%). Sta. aureus was more prevalent more in eyelid infections (51.22%; P = 0.001) coagulase-negative staphylococci in endophthalmitis (53.1%; P = 0.001), Str. pneumoniae in lacrimal apparatus and corneal infections (64.19%; P = 0.001), Corynebacterium species in blepharitis and conjunctivitis (71%; P = 0.001), Pseudomonas aeruginosa in keratitis and dacryocystitis (66.5%; P = 0.001), Haemophilus species in dacryocystitis and conjunctivitis (66.7%; P = 0.001), Moraxella lacunata in blepharitis (54.17%; P = 0.001) and Moraxella catarrhalis in dacryocystitis (63.83%; P = 0.001). The largest number of gram-positive isolates was susceptible to moxifloxacin (98.7%) and vancomycin (97.9%), and gram-negative isolates to amikacin (93.5%) and gatifloxacin (92.7%). CONCLUSIONS: Gram-positive cocci were the most frequent bacteria isolated from ocular infections and were sensitive to moxifloxacin and vancomycin, while gram-negative isolates were more sensitive to amikacin and gatifloxacin.

Analysis of the risk factors predisposing to fungal, bacterial & Acanthamoeba keratitis in south India.

BACKGROUND & OBJECTIVE: Infective keratitis is rare in the absence of predisposing factors. The pattern of risk factors predisposing to infective keratitis varies with geographical regions and also influences the type of infection that occurs. The present study was aimed to identify the specific risk factors that predispose the infective keratitis (non viral) and to determine the association between the risk factors identified and the microbial aetiology of infective keratitis in a geographic region (south India). METHODS: A retrospective analysis of all patients clinically diagnosed infective keratitis (non viral) presenting between September 1999 and September 2002 was performed to identify risk factors. After diagnosing infective keratitis clinically, corneal scrapes were performed and subjected to microscopy and culture. RESULTS: A total of 3295 patients with infective keratitis were evaluated, of whom, 1138 (34.5%) patients had fungal growth alone, 1066 (32.4%) had bacterial growth alone, 33 (1%) had Acanthamoeba growth alone, 83 (2.5%) had mixed microbial growth and the remaining 975 (29.6%) had no growth. Corneal injury was identified in 2356 (71.5%) patients and it accounted for 91.9 per cent in fungal keratitis (P<0.0001) (OR: 73.5; 95%CI: 61.3-98.5), 28.1 per cent in bacterial keratitis and 100 per cent in Acanthamoeba keratitis (P<0.0001). Injuries due to vegetative matter (61.2%) was identified as significant risk for fungal keratitis (P<0.0001) (OR: 15.73; 95%CI: 12.7-19.49) and mud (84.85%) for Acanthamoeba keratitis (P<0.0001) (OR: 16.52; 95%CI: 6.35-42.99). Co-existing ocular diseases predisposing to bacterial keratitis accounted for 724 (69%) patients (P<0.0001) (OR: 33.31; 95%CI: 26.98-41.12). Bacterial pathogens alone were recovered from all 35 patients with contact lens associated keratitis (100%). Co-existing ocular diseases (78.3%) were frequently documented among patients older than 50 yr (P<0.0001) (OR: 27.0; 95%CI: 25.0-28.0) and corneal injury (89.7%) was frequently recorded among patients younger than 51 yr (P<0.0001) (OR: 72.0; 95%CI: 70.0-73.0). INTERPRETATION & CONCLUSION: Corneal injury was found to be the principal risk factor for fungal and Acanthamoeba keratitis, while co-existing ocular diseases for bacterial keratitis. Corneal injury with vegetative matter was more often associated with fungal keratitis and injury with mud with Acanthamoeba keratitis.

Comparative bacteriology of acute and chronic dacryocystitis.

AIMS: To compare the bacterial aetiology and their in vitroantibacterial susceptibilities of acute and chronic dacryocystitis. METHODS: A retrospective analysis of patients with clinically diagnosed acute and chronic dacryocystitis who underwent microbiological evaluation presenting between January 2000 and December 2005 was carried out. Mucopurulent discharge through punctum, pus from burst abscess, incision drainage, and lacrimal sac content were taken and subjected to microbiological evaluation. RESULTS: A total of 1891 patients of dacryocystitis were evaluated and subjected to microbiological evaluation, of which 566 (29.9%) had acute dacryocystitis and 1325 (70.1%) had chronic dacryocystitis. Of 1891 eyes, 1518 (80.3%) had pure bacterial growth and the remaining 373 (19.7%) had no growth. The percentage of culture-positivity was found to be higher in chronic dacryocystitis (90%) than in acute dacryocystitis (57.4%) (P<0.0001). A total of 1612 bacterial isolates were recovered from 325 acute and 1193 chronic dacryocystitis; in 1424 (93.8%) eyes, single bacterial species was isolated, and in the remaining 94 (6.2%) eyes, two bacterial species were isolated. The predominant bacterial pathogen isolated from acute dacryocystitis was Staphylococcus aureus(22.3%) followed by Pseudomonas aeruginosa(21.1%) and from chronic dacryocystitis was coagulase-negative staphylococci (CoNS) (44.2%), S. aureus(10.8%), and Streptococcus pneumoniae(10%). The highest percentage of bacterial isolates were susceptible to gatifloxacin (96.5%), ofloxacin (94.8%), and amikacin (91.1%). The percentage of resistance of bacterial isolates recovered from chronic dacryocystitis to gentamicin (45.7%), tobramycin (50.8%), norfloxacin (50.7%), and ciprofloxacin (30.4%) were found to be higher than that of bacterial isolates from acute infection to gentamicin (24.6%), tobramycin (35%), norfloxacin (36.5%), and ciprofloxacin (19.9%). CONCLUSION: The proportions of S. aureusand Pseudomonasspp are higher in causing acute dacryocystitis, while the proportion of CoNS is higher in chronic dacryocystitis. The percentages of antibacterial resistant isolates were higher among bacterial species from chronic dacryocystitis.

Microbial keratitis in South India: influence of risk factors, climate, and geographical variation.

PURPOSE: To determine the influence of risk factors, climate, and geographical variation on the microbial keratitis in South India. METHODS: A retrospective analysis of all clinically diagnosed infective keratitis presenting between September 1999 and August 2002 was performed. A standardised form was filled out for each patient, documenting sociodemographic features and information pertaining to risk factors. Corneal scrapes were collected and subjected to culture and microscopy. RESULTS: A total of 3,183 consecutive patients with infective keratitis were evaluated, of which 1,043 (32.77%) were found to be of bacterial aetiology, 1,095 (34.4%) were fungal, 33 (1.04%) were Acanthamoeba, 76 (2.39%) were both fungal and bacterial, and the remaining 936 (29.41%) were found to be culture negative. The predominant bacterial and fungal pathogens isolated were Streptococcus pneumoniae (35.95%) and Fusarium spp. (41.92%), respectively. Most of the patients (66.84%) with fungal keratitis were between 21 and 50 years old, and 60.21% of the patients with bacterial keratitis were older than 50 (p < 0.0001) (95% CI: 5.19-7.19). A majority of patients (64.75%) with fungal keratitis were agricultural workers (p < 0.0001) [odds ratio (OR): 1.4; 95% CI: 1.19-1.61], whereas bacterial keratitis occurred more commonly (57.62%) in nonagricultural workers (p < 0.0001) (OR: 2.88; 95% CI: 2.47-3.36). Corneal injury was identified in 2,256 (70.88%) patients, and it accounted for 92.15% in fungal keratitis (p < 0.0001) (OR: 7.7; 95% CI: 6.12-9.85) and 100% in Acanthamoeba keratitis. Injuries due to vegetative matter (61.28%) were identified as a significant cause for fungal keratitis (p < 0.0001) (OR: 23.6; 95% CI: 19.07-29.3) and due to mud (84.85%) for Acanthamoeba keratitis (p < 0.0001) (OR: 26.01; 95% CI: 3.3-6.7). Coexisting ocular diseases predisposing to bacterial keratitis accounted for 68.17% (p < 0.0001) (OR: 33.99; 95% CI: 27.37-42.21). The incidence of fungal keratitis was higher between June and September, and bacterial keratitis was less during this period. CONCLUSION: The risk of agricultural predominance and vegetative corneal injury in fungal keratitis and associated ocular diseases in bacterial keratitis increase susceptibility to corneal infection. A hot, windy climate makes fungal keratitis more frequent in tropical zones, whereas bacterial keratitis is independent of seasonal variation and frequent in temperate zones. Microbial pathogens show geographical variation in their prevalence. Thus, the spectrum of microbial keratitis varies with geographical location influenced by the local climate and occupational risk factors.

Microbiological diagnosis of infective keratitis: comparative evaluation of direct microscopy and culture results.

AIMS: To determine the sensitivity, specificity and predictive values of potassium hydroxide (KOH) wet mount, Gram stain, Giemsa stain and Kinyoun's acid-fast stain in the diagnosis of infective keratitis. METHODS: A retrospective analysis of all patients with clinically diagnosed infective keratitis presenting between September 1999 and September 2002 was carried out. Corneal scrapes were taken and subjected to direct microscopy and culture. RESULTS: 3298 eyes of 3295 consecutive patients with infective keratitis were evaluated, of which 1138 (34.51%) eyes had fungal growth alone, 1069 (32.41%) had bacterial growth alone, 33 (1%) had Acanthamoeba growth alone, 83 (2.5%) had mixed microbial growth and the remaining 975 (29.56%) had no growth. The sensitivity of KOH wet mount was higher (99.3%; 95% confidence interval (CI) 98.6 to 99.6) in the detection of fungi, 100% (95% CI 90.4 to 100) in the detection of Nocardia and 91.4% (95% CI 75.8 to 97) in the detection of Acanthamoeba) than that of Gram-stained smears (89.2% (95% CI 87.3 to 90.8) in fungi, 87% (95% CI 73.0 to 94.6) in Nocardia and 60% (95% CI 42.2 to 75.6) in the detection of Acanthamoeba) in the detection of fungi, Nocardia and Acanthamoeba. 1764 of 3295 (53.54%) patients presented more than 7 days after onset of illness and 84.69% of the eyes had corneal ulcers with size >2 mm in diameter. Positivities of KOH (44.46%; p<0.001) and Gram-stained smears (77.37%; p<0.001) were found to be higher among eyes with larger ulcers (>2 mm) than among eyes with smaller ulcers (<2 mm). CONCLUSION: KOH smear is of greater diagnostic value in the management of infective keratitis, and it is recommended in all clinics without exception for establishing timely treatment.

Problematic formulations of SAS PROC.MIXED models for repeated measurements.

The work reported in this article was undertaken to evaluate the utility of SAS PROC.MIXED for testing hypotheses concerning GROUP and TIME x GROUP effects in repeated measurements designs with drop-outs. If dropouts are not completely at random, covariate control over informative individual differences on which dropout data patterns depend is widely recognized to be important. However, the inclusion of baseline scores and time-in-study as between-subject covariates in an otherwise well formulated SAS PROC.MIXED model resulted in inadequate control over type I error in simulated data with or without drop-outs present. The inadequate model formulations and resulting deviant test sizes are presented here as a warning for others who might be guided by the same information sources to employ similar model specifications when analyzing data from actual clinical trials. It is important that the complete model specification be provided in detail when reporting applications of the general linear mixed-model procedure. A single random-coefficients model produced appropriate test sizes, but it provided inferior power when informative covariates were added in the attempt to adjust for dropouts. As an alternative, the incorporation of covariate controls in simpler two-stage endpoint or random regression analyses is documented to be effective in dealing with dropouts under specifiable conditions.

Testing differences in response trends across a normalized time domain.

A two-stage mixed model analysis of repeated measurement calculates participant-specific regression slopes relating change in available measurements to associated assessment times, and then the difference between mean regression slopes in two or more treatment groups is tested for significance against the within-groups variability of the participant-specific regression slopes. It is not necessary that all participants have the same schedule or number of repeated measurements. However, when dropouts are included in an "intent to treat" analysis, the shortened treatment exposures for the dropouts substantially increase variability and reduce power of tests for differences in rates of change. Previous work has suggested that normalizing the time scale to unit length for all participants prior to fitting the individual regression equations materially reduces the power attenuation produced by dropouts. This article reports a more detailed evaluation of the enhanced robustness against dropouts that is achieved by rescaling the time dimension. The robust analysis is recognized to be equivalent to weighting ordinary least squares regression on the original time scale by the duration of treatment for each participant. Slope coefficients calculated across a shortened time span for dropouts are less stable, so they are given less weight in defining the (linear) treatment effects.

The A enhancer of polyomavirus: protein-protein interactions for the differential early and late promoter function under nonreplicating conditions.

The A enhancer of the polyomavirus early promoter is a 110-bp domain located in the late region and it contains the major late RNA initiation site. The 'core' of this enhancer binds several cellular proteins, including proteins PEA1, PEA2 and PEA3. Another element, NF-D/YY1, is also located in this enhancer. The A enhancer is known to stimulate the early promoter, contains auxiliary elements for replication and serves as the initiator for late transcription. It may also be involved in early-to-late switch. We were interested in investigating how the A-core- and NF-D-binding proteins regulate early and late promoter activity under nonreplicating conditions and how the protein-protein interactions affect the function of the individual elements. By point mutational analysis, we show that, except for PEA1, all other proteins activate the early and late promoters differentially under nonreplicating conditions. All three core-binding proteins, and the protein bound to the NF-D site, are activators and have a combinatorial effect on early promoter activity. On late transcription, only PEA1 acts positively and inactivation of the NF-D site is without any effect. In contrast, PEA2 and PEA3 have a repressor-like activity under nonreplicating conditions, indicating that these two proteins might be involved in repressing late transcription, probably early in infection. By increasing the spacing between two consecutive elements, we further show that protein-protein interaction is important for enhancer function. Transactivation of the early promoter was affected by mutations in all four protein-binding sites. Responsiveness of these factors in regard to the late promoter was parallel to their intrinsic promoter strength. The effects of middle and large T antigens are parallel for both the early and the late promoter, suggesting that the pathway(s) for transactivation function of these oncoproteins may overlap downstream. This study with cloned viral promoter will be reflective of situations in vivo, at least partially, under nonreplicating conditions.

GeneFIND web server for protein family identification and information retrieval.

UNLABELLED: An integrated database and search system has been developed for protein family identification and information retrieval, as an approach to undertake the highly complex, genomic-scale problem of molecular sequence database search and organization. AVAILABILITY: http://diana.uthct.edu CONTACT: wu@uthct.edu

Adjusting sample size for anticipated dropouts in clinical trials.

Statistical models for calculating sample sizes for controlled clinical trials often fail to take into account the negative impact that dropouts have on the power of intent-to-treat analyses. Empirically defined dropout correction coefficients are proposed to adjust sample sizes for endpoint analysis of variance (ANOVA) and analysis of covariance (ANCOVA) that have been initially calculated assuming complete data. The implications of type of analysis (change-score ANOVA or ANCOVA), correlational structure of the repeated measurements (compound symmetry or autoregressive), and percentage of dropouts (20% or 30%) are considered, together with other less influential design and data parameters. We recommend the use of ANCOVA to correct for baseline differences and for time-in-study if there is a nonspecific change across time. Given a realistic autoregressive (order 1) correlational structure for the repeated measurements and a proposed endpoint ANCOVA, the empirical results support the common practice of increasing calculated sample size by the anticipated number of dropouts. The previous rationale has been to retain a requisite number of "completers" on which to base statistical inferences. We believe the present results provide the first documentation of the relevance of that strategy for intent-to-treat analyses in which the incomplete data for dropouts must be included. Based on comparative power analyses, the strategy also seems appropriate for maintaining the power of mixed-model regression analyses, simple regression on a normalized time scale, and analyses of trends fitted to imputed scores for dropouts.

Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

The human epidermal growth factor receptor (EGFR) promoter is activated by both wild-type and tumor-derived mutant p53. In this communication, we demonstrate that EGFR promoter sequence requirements for transactivation by wild-type and mutant p53 are different. Transient-expression assays with EGFR promoter deletions identified a wild-type human p53 response element, 5'-AGCTAGACGTCCGGGCAGCCCCCGGCG -3', from positions --265 to --239. Electrophoretic mobility shift analysis and DNase I footprinting assays indicated that wild-type p53 binds sequence specifically to the response element. Using circularly permuted DNA fragments containing the p53-binding site, we show that wild-type p53 binding induces DNA bending at this site. We further show that the EGFR promoter is also activated by tumor-derived p53 mutants p53-143A, p53-175H, p53-248W, p53-273H, and p53-281G. However, the transactivation by mutant p53 does not require the wild-type p53-binding site. The minimal EGFR promoter from positions --104 to --20 which does not contain the wild-type p53-binding site is transactivated by the p53 mutants but not by the wild-type protein, showing a difference in the mechanism of transactivation by wild-type and mutant p53. Transactivation of the EGFR promoter by p53 may represent a novel mechanism of cell growth regulation.

Interaction of human polyomavirus BK with the tumor-suppressor protein p53.

We have been studying the interaction of the oncogenic human polyomavirus BK (BKV) with the tumor-suppressor protein p53 to understand the biology of this virus as well as to understand the basic mechanisms of p53 transactivation. We here demonstrate that p53 binds specifically to the viral promoter at two different sites, S-I (np 361-383) and S-II (np 314-336) in the late region. Site S-I is a 23 bp domain comprising an unique combination of a 10 bp consensus monomer binding site (Pu Pu Pu C (A/T) (T/A) G Py Py Py) which is contiguous with a GC-rich Sp-1 motif that binds p53 in the SV40 promoter. Site S-II also spans a 23 bp sequence containing two tandem consensus binding sites with three base pair mismatches in each and a one base pair deletion. A dimer of a 100 bp region spanning both the binding sites or the site S-I alone induced p53 responsiveness to a basal promoter when cloned upstream from the TATA box, but a similar construct using S-II did not. One tumor-derived mutant protein, p53-175 H, which is defective in DNA binding, also failed to transactivate the reporter gene. We further show that p53 binding-dependent transactivation is abrogated by BKV large T antigen, thereby suggesting an interaction between these two proteins in vivo. In contrast to the isolated p53 binding site, viral early promoter is repressed by p53 in H 1299 cells and the mutants are defective in this function to varying extent. This is suggestive of an involvement of cellular factors in modulating p53's function in the context of the whole promoter. p53 binding sites in BKV are flanked by the binding sites for transcription factors Sp-1 and NF-1 and we show that these transcription factors are present in the immunocomplex with purified p53, implicating modification of p53's transactivation function by protein-protein interaction. Thus, oncoprotein synthesis in this virus might be modulated by p53 in vivo by a complex mechanism other than simple DNA binding and sequestration of the TATA binding protein. Together with SV40 and polyomavirus, which also harbor p53 binding sites, this viral system will serve as a model to understand the role of p53 in viral infection.

The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53.

We have examined the interaction of the wild-type p53 protein with the downstream promoter of the human multidrug resistance gene-1 (MDR1). Our findings indicate that wild-type p53 inhibits reporter activity driven by the MDR1 downstream promoter (base pairs -189 to +133 relative to the major transcriptional initiation site) in a dose-dependent manner in cotransfection assays in the BHK and the Saos-2 cell lines. A 123 base-pair segment of DNA (-119 to +4 relative to the major transcriptional initiation site), a 193 base-pair segment (-189 to +4), and a 135 base-pair segment (-2 to +133) have been isolated from the MDR1 downstream promoter which, like the full promoter, are negatively controlled by wild-type p53. In addition, we show sequence-specific binding of wild-type p53 protein to the MDR1 downstream promoter. These in vitro results suggest that the presence of wild-type p53 negatively affects expression of the MDR1 gene product, p-glycoprotein, at the transcriptional level.

Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter.

The wild-type p53 protein is a transcriptional activator implicated in the control of cellular growth-related gene expression. Here, using a number of different cell lines and transient-transfection-transcription assays, we demonstrate that at low levels, wild-type p53 transactivates the human proliferating cell nuclear antigen (PCNA) promoter. When expressed at a similar level, the tumor-derived p53 mutants did not transactivate the PCNA promoter. We identified a p53-binding site on the human PCNA promoter with which p53 interacts sequence specifically. When placed on a heterologous synthetic promoter, the binding site functions as a wild-type p53 response element in either orientation. Deletion of the p53-binding site renders the PCNA promoter p53 nonresponsive, showing that wild-type p53 transactivates the PCNA promoter by binding to the site. At a higher concentration, wild-type p53 inhibits the PCNA promoter but p53 mutants activate. Transactivation by p53 mutants does not require the p53-binding site. These observations suggest that moderate elevation of the cellular wild-type p53 level induces PCNA production to help in DNA repair.

N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.

The human oncoprotein MDM2 binds with the tumor suppressor p53 and inhibits p53-directed transactivation. In this report we show that deletion of 336 amino acids from the C-terminus of human MDM2 does not decrease its efficiency to bind p53 in vivo and inhibit p53-directed transactivation. Even further deletion of MDM2 from the C-terminus up to amino acid 131 does not reduce its ability to inhibit p53-mediated transactivation. Since deletion up to amino acid 131 also deletes many antigenic sites of MDM2 and the truncated protein cannot be immunoprecipitated by the antibodies available to us, two internal deletions were made to define the p53-interaction domain. Internal deletion of four amino acids beginning at 110 residue (amino acids 110 to 113) did not reduce p53-binding or inhibition of p53-directed transactivation whereas internal deletion of amino acids 60 to 65 reduces but does not abolish these activities. Sequential deletion of amino acids from the N-terminus leads to sequential destruction of p53-binding and inhibition of transactivation capability of MDM2. Fourteen amino acids can be deleted from this end without any reduction of these activities. Deletion of 28 N-terminal amino acids residues drastically reduces, but does not abolish the p53-binding ability of the protein, as well as inhibition of p53-directed transactivation. Deletion of 58 amino acids from the N-terminus of the oncoprotein abolishes its ability to bind p53 in vivo and to inhibit p53-directed transactivation. These results locate the p53-binding domain of MDM2 within amino acids 14 to 154 and inhibition of transactivation domains of MDM2 within amino acid residues 14 to 130 suggesting possible p53-independent biological functions of the 491 amino acid long oncoprotein.